While US FDA Commissioner Scott Gottlieb touted the 21st Century Cures Act's inclusion of the limited population antibacterial drug (LPAD) pathway as a way to spur antibiotics to market, he stressed the need for pull incentives focusing on the reimbursement of limited use anti-infectives.
The agency is working on one such step with the Centers for Medicare and Medicaid Services (CMS), Gottlieb explained at a July 25 House Energy and Commerce Subcommittee on Health hearing, which involves an attempt "to move toward a different reimbursement paradigm
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?